ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Health Technology

AnGes, Inc.

Business Summary

AnGes, Inc. engages in the research and development of gene-based medical products. It offers genetic medicines such as hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, and others. It is also involved in the research and development of medical equipment, which improves blood circulation by regenerating blood vessels and NfkB which controls various inflammations. The company was founded on December 17, 1999 and is headquartered in Ibaraki, Japan.

Financial Highlights

Dec 2020 JPYUSD
Revenue39.99M0.37M
Gross Profit12.06M0.11M
Operating income-5,599.39M-52.44M
Income before tax-4,204.95M-39.38M
Net income-4,209.51M-39.42M
EBITDA-5,591.80M-52.37M
Diluted EPS-35.32-0.33
Dividends Per Share00
Total Assets38,354.61M371.49M
Total liabilities5,674.93M54.96M
Total equity32,679.67M316.52M
Operating cash flow-2,961.32M-27.73M
Currency in JPYCurrency in USD

Historical Data

 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 514.26M 365.18M 610.05M 326.75M 39.99M
Gross Profit 281.91M 163.69M 418.87M 235.16M 12.06M
Operating income -4,615.47M -3,288.68M -3,065.25M -3,270.00M -5,599.39M
Income before tax -4,760.67M -3,744.18M -3,003.00M -3,751.60M -4,204.95M
Net income -4,776.78M -3,764.69M -2,996.62M -3,750.82M -4,209.51M
EBITDA -4,548.16M -3,259.32M -3,057.39M -3,262.68M -5,591.80M
Diluted EPS -75.29 -49.38 -34.46 -35.81 -35.32
Dividends Per Share 0 0 0 0 0
Total Assets 4,539.20M 3,963.60M 8,050.67M 12,524.60M 38,354.61M
Total liabilities 669.81M 341.72M 316.21M 469.24M 5,674.93M
Total equity 3,869.38M 3,621.88M 7,734.45M 12,055.35M 32,679.67M
Operating cash flow -4,983.69M -2,991.22M -2,522.50M -2,179.91M -2,961.32M
 Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020
Revenue 4.73M 3.25M 5.52M 2.99M 0.37M
Gross Profit 2.59M 1.45M 3.79M 2.15M 0.11M
Operating income -42.47M -29.32M -27.75M -29.99M -52.44M
Income before tax -43.81M -33.39M -27.19M -34.41M -39.38M
Net income -43.96M -33.57M -27.13M -34.40M -39.42M
EBITDA -41.85M -29.06M -27.68M -29.92M -52.37M
Diluted EPS -0.69 -0.44 -0.31 -0.32 -0.33
Dividends Per Share 0 0 0 0 0
Total Assets 38.91M 35.18M 73.37M 115.24M 371.49M
Total liabilities 5.74M 3.03M 2.88M 4.31M 54.96M
Total equity 33.17M 32.15M 70.49M 110.93M 316.52M
Operating cash flow -45.86M -26.67M -22.83M -19.99M -27.73M

Valuation Measures

Dec 2020
PER--
ROA-16.54%
ROE-18.81%
Operating margin-13,999.17%
Profit margin-10,524.30%

Key executives

  • President & Representative Director: Ei Yamada
  • Director, Executive Officer & Manager-Finance: Tetsuji Yoneo
  • Director & Manager-Drug Discovery Research: Kazuo Suzuki
  • Executive Officer, Manager-R&D Promotion: Hajime Watanabe
  • Manager-Accounting: Jun Sakurai

Shareholders

  • OrbiMed Advisors Private Equity (3.8%)
  • BlackRock Fund Advisors (1.0%)
  • Shionogi & Co., Ltd. (0.7%)
  • JPMorgan Asset Management (UK) Ltd. (0.4%)
  • MORISHITA RYUICHI (0.4%)
  • MAGARIBUCHI NAOKI (0.2%)
  • BlackRock Advisors (UK) Ltd. (0.1%)
  • TIAA-CREF Investment Management LLC (0.0%)
  • SSgA Funds Management, Inc. (0.0%)
  • Credit Suisse Asset Management (Schweiz) AG (0.0%)

Contact Details

  • Website:http://www.anges.co.jp
  • Address: Saito Bio-Incubator, 1/F, 7-7-15 Saito-Asagi, Osaka, 567-0085, Japan
  • Phone: +81.72.643.3590

Related Companies

  • Emendo Biotherapeutics, Inc.
  • AnGes USA, Inc.
  • AnGes Euro Ltd.

Competitors

  • Defence Therapeutics Inc Class A
  • Cellid Co., Ltd.
  • Sienna Biopharmaceuticals, Inc.
  • Athira Pharma, Inc.
Last Updated on 27 Sep, 2021

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more